In a report released today, Stephen Willey from Stifel Nicolaus maintained a Buy rating on Xenon (XENE). The company’s shares closed yesterday at $9.63.
According to TipRanks.com, Willey is a 5-star analyst with an average return of 21.1% and a 50.0% success rate. Willey covers the Healthcare sector, focusing on stocks such as Lexicon Pharmaceuticals, Conatus Pharmaceuticals, and Inovio Pharmaceuticals.
The the analyst consensus on Xenon is currently a Hold rating.
See today’s analyst top recommended stocks >>
The company has a one-year high of $15.92 and a one-year low of $4.50. Currently, Xenon has an average volume of 107K.
Based on the recent corporate insider activity of 10 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of XENE in relation to earlier this year. Earlier this month, Michael R. Hayden, a Director at XENE bought 20,576 shares for a total of $69,547.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Xenon Pharmaceuticals, Inc. engages in discovering and developing therapeutics to improve the lives of patients with neurological disorders. It focuses on the treatment of epilepsy. Its products include XEN496, XEN1101, XEN901, and XEN007.
